Resistance to KRAS G12C Inhibition in Non-Small Cell Lung Cancer

The authors provide a comprehensive overview of the mechanisms that limit the efficacy of KRASG12C inhibitors and review potential strategies to overcome and possibly delay the development of resistance in patients receiving KRAS-directed targeted therapies.